Dr. Lisa Jackson of Kaiser Permanente Washington Health Research Institute in Seattle and colleagues conducted a first-in-human Phase 1 clinical trial in healthy adults to evaluate the safety and immunogenicity of an investigational anti-SARS-CoV-2 vaccine called mRNA-1273. According to their report published in the New England Journal of Medicine, the vaccine candidate was generally well tolerated and prompted neutralizing antibody activity in all...
